BreezeBio closed a $60 million financing to propel clinical testing of its first mRNA program for diabetes and to pivot from earlier GenEdit plans toward proprietary therapeutics. The startup—now repositioned to advance in‑house candidates—will use the proceeds to begin human testing of an mRNA diabetes therapy and to develop a tolerance‑inducing approach for Type 1 diabetes. BreezeBio's funding and rebrand mark a broader industry push to commercialize novel delivery platforms for RNA medicines beyond vaccines.